HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma.

Abstract
We previously reported that RGD fiber-mutant adenovirus vector (AdRGD) was a very useful vector system for in vivo cytokine gene therapy for established murine B16BL6 melanoma. However, intratumoral administration of AdRGD expressing tumor necrosis factor alpha (AdRGD-TNFalpha) at high dose revealed not only the dramatic reinforcement of anti-tumor effect but also serious adverse effects, such as body weight reduction and sudden death, caused by high-level TNF-alpha leakage from the tumor into circulation. These results strongly suggested that the determination of 'limiting dose', which demonstrated therapeutic effectiveness without adverse effect, against each vector was important for the development of appropriate cytokine gene therapy. In the present study, we investigated the efficacy and the safety of AdRGD expressing interleukin-12 (AdRGD-IL12) in murine melanoma model, and determined its limiting dose. Moreover, we demonstrated that combination therapy using AdRGD-IL12 and AdRGD-TNFalpha at limiting doses or less could achieve more effective tumor regression without adverse effects. Therefore, we conclude that a combination of multiple AdRGD expressing cytokines having distinct anti-tumor mechanisms can contribute to the establishment of in vivo cytokine gene therapy for melanoma, which possesses both excellent efficacy and high safety.
AuthorsYuka Okada, Naoki Okada, Hiroyuki Mizuguchi, Koichi Takahashi, Takao Hayakawa, Tadanori Mayumi, Nobuyasu Mizuno
JournalBiochimica et biophysica acta (Biochim Biophys Acta) Vol. 1670 Issue 3 Pg. 172-80 (Feb 24 2004) ISSN: 0006-3002 [Print] Netherlands
PMID14980444 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Cytokines
  • Oligopeptides
  • Tumor Necrosis Factor-alpha
  • Interleukin-12
  • arginyl-glycyl-aspartic acid
  • Interferon-gamma
Topics
  • Adenoviridae (chemistry, genetics)
  • Animals
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Body Weight
  • Cytokines (biosynthesis, genetics, therapeutic use)
  • Female
  • Genetic Therapy (methods)
  • Genetic Vectors (therapeutic use)
  • Injections, Intralesional
  • Interferon-gamma (analysis)
  • Interleukin-12 (biosynthesis, genetics, immunology)
  • Killer Cells, Natural (immunology)
  • Melanoma, Experimental (pathology, therapy)
  • Mice
  • Mice, Inbred C57BL
  • Oligopeptides (chemistry, genetics)
  • Spleen (immunology)
  • Time Factors
  • Transduction, Genetic
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha (biosynthesis, genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: